Factors involved in body weight loss and its maintenance in morbidly obese inpatients
- 16 Downloads
Body weight loss in patients with obesity improves abnormal glucose tolerance, dyslipidemia and hypertension; however, it is difficult to maintain this loss of body weight. The objective of this study was to examine factors involved in body weight loss and its maintenance in morbidly obese inpatients.
The subjects were 31 patients (11 males and 20 females) who were admitted to hospital for obesity management. Factors involved in body weight changes during hospitalization and after discharge were examined retrospectively. The mean age was 58.1 ± 13.6 years and body mass index (BMI) was 40.2 ± 10.2 kg/m2. Twenty-four patients were complicated with type 2 diabetes mellitus. Diet therapy was 23.8 ± 3.9 kcal/kg ideal body weight/day.
Excess weight loss (EWL) during hospitalization varied from 4.2 to 61.7%. Since EWL was affected by duration of hospital stay, the subjects were divided by the median of EWL per day. The subjects with greater EWL per day had lower body weight, BMI and fat mass on admission in the entire (n = 31), diabetic (n = 24), and non-diabetic subjects (n = 7), respectively. EWL per day was not different between diabetic and non-diabetic subjects. Follow-up data revealed that BMI remained unchanged 3 months after discharge but modestly increased 1 year after discharge, irrespective of EWL per day during hospitalization. In diabetic subjects followed up 1 year after discharge (n = 15), the increase in body weight was smaller than that in non-diabetic subjects (n = 3).
These results suggest that EWL in morbidly obese inpatients is greater than those with lower baseline BMI and fat mass. The presence of diabetes had no effects on EWL during hospitalization. EWL during hospitalization was not correlated with its maintenance after discharge. Diabetic patients displayed lesser degree of body weight gain after discharge, possibly due to the effects of anti-diabetic medications.
KeywordsObesity Excess weight loss Rebound Diabetes mellitus
Compliance with ethical standards
Conflict of interest
All authors declare that they have no conflict of interest.
Research involving human participants
The study was conducted after approval by the institutional review board of Showa University Fujigaoka Hospital (Date of approval: Aug 15, 2016, Approval number: 2016045). The summary of the study objectives and research details was acknowledged on our website because of the retrospective design. An appropriate opportunity for refusal regarding use of medical records was provided. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
- 1.Committee on Obesity Diagnostic Criteria of the Japan Society for the Study of Obesity. New diagnostic criteria for obesity. Obes Res. 2000;6:18–28.Google Scholar
- 4.Japan Society for the Study of Obesity. Guidelines for obesity treatment in 2016. 1st ed. Tokyo: Life Science Publishing; 2016. p. 48–57.Google Scholar
- 7.Heianza Y, Ma W, Huang T, Wang T, Zheng Y, Smith SR, Bray GA, Sacks FM, Qi L. Macronutrient intake-associated FGF21 genotype modifies effects of weight-loss diets on 2-year changes of central adiposity and body composition: the POUNDS lost trial. Diabetes Care. 2016;39:1909–14.CrossRefGoogle Scholar
- 11.Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1:212–28.CrossRefGoogle Scholar
- 14.Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, Champagne CM, Bishop LM, Laranjo N, Leboff MS, Rood JC, de Jonge L, Greenway FL, Loria CM, Obarzanek E, Williamson DA. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360:859–73.CrossRefGoogle Scholar
- 19.Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, Hare MJL, Calder GL, Epa DS, George EM, Giri R, Kotowicz MA, Kyi M, Lafontaine N, MacIsaac RJ, Nolan BJ, O’Neal DN, Renouf D, Varadarajan S, Wong J, Xu S, Bach LA. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019. https://doi.org/10.1210/jc.2019-00139.Google Scholar
- 22.Yoshimura E, Ohkawara K, Ishikawa-Takata K, Yamada S, Tokui M, Funae O, Takimoto H, Katsukawa F. Assessment of energy expenditure using doubly labeled water, physical activity by accelerometer and reported dietary intake in Japanese men with type 2 diabetes: a preliminary study. J Diabetes Investig. 2018. https://doi.org/10.1111/jdi.12921.Google Scholar
- 24.Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, Pi-Sunyer X, Kalyani RR, Franks PW, Srikanthan P, Gadde KM, Diabetes Prevention Program Research Group. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019;170:682–90.CrossRefGoogle Scholar